Cubist Pharmaceuticals, Inc.
Company reports Q4 Cubicin revenues of $21.0M, year-end net revenue of $58.6M
Published in Drug Law Weekly, February 8th, 2005
This is an increase of 17%, or $3 million, from third-quarter 2004 Cubicin revenue. Full 2004 year-end net revenues were $58.6 million (unaudited) which is in the high end of the company's 2004 earnings revenue guidance of $55-60 million.
Michael W. Bonney, president and CEO, stated, "With just over a full year of sales now completed, we take great pride in the confirmation that the launch of Cubicin is in fact the most successful IV [intravenous]...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
Source: Drug Law Weekly (2005-02-08)
More Articles from Drug Law Weekly
- Abbott Laboratories
Indiana Circuit Court denies class certification in OxyContin litigation - Beckman Coulter, Inc.
Exclusive license agreement signed for intellectual property - BioVeris Corporation
Agreements completed with Children's Hospital & Research Center at Oakland - Biophan Technologies, Inc.
Biomedical technology firm executes letter of intent to acquire MRI company - Biophan Technologies, Inc.
Company's biomedical intellectual property portfolio crosses 100-patent mark - Bruckner Group
Biotechnology drug revenues will be hard hit by strict benefit management - More from this issue of Drug Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
